{"nctId":"NCT03719586","briefTitle":"Investigational Therapeutics for the Treatment of People With Ebola Virus Disease","startDateStruct":{"date":"2018-11-21","type":"ACTUAL"},"conditions":["Ebola Virus"],"count":681,"armGroups":[{"label":"A","type":"EXPERIMENTAL","interventionNames":["Drug: Remdesivir"]},{"label":"B","type":"EXPERIMENTAL","interventionNames":["Drug: MAb114"]},{"label":"C","type":"EXPERIMENTAL","interventionNames":["Drug: REGN-EB3"]},{"label":"Control","type":"EXPERIMENTAL","interventionNames":["Drug: ZMapp"]}],"interventions":[{"name":"ZMapp","otherNames":[]},{"name":"Remdesivir","otherNames":[]},{"name":"MAb114","otherNames":[]},{"name":"REGN-EB3","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"* INCLUSION CRITERIA:\n* Males or females of any age with documented positive RT-PCR in blood for acute Ebola virus infection within 3 days prior to enrollment and who have symptoms of any duration.\n* Willingness of study participant to accept randomization to any assigned treatment arm.\n* All males and females of childbearing potential must be willing to use effective methods of contraception, from time of enrollment until Day 58 of study.\n* Must agree not to enroll in another study of an investigational agent prior to completion of Day 28 of study.\n* Ability to provide informed consent personally, or by a legally acceptable representative if the patient is unable to do so.\n\nEXCLUSION CRITIERA:\n\n* Patients who, in the judgment of the investigator, will be unlikely or unable to comply with the requirements of this protocol through Day 28.\n* Prior treatment with any investigational antiviral drug therapy against Ebola virus infection within 5 half-lives or 30 days, whichever is longer, prior to enrollment. (Patients who have received an experimental (or, in future, potentially a licensed) immunization against Ebola virus remain eligible.)","healthyVolunteers":false,"sex":"ALL","maximumAge":"99 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mortality","description":"Number of Participants with Mortality by Day 28","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"61","spread":null},{"groupId":"OG002","value":"52","spread":null},{"groupId":"OG003","value":"84","spread":null}]}]}]},{"type":"SECONDARY","title":"Time in Days to First Negative Ebola Virus RT-PCR in Blood.","description":"This was a measure of the median number of days that it took for the serum PCR to first turn negative after having been positive throughout the patient's earlier course.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"15","spread":null},{"groupId":"OG003","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"Viremia as Determined by CTnp Values on PCR","description":"These are the median CTnp pCR values measured serially on the 4 treatment arms as per protocol.\n\ncaveats: Undetectable ctNP values are imputed as ctNP=45.0 (the limit of detection). Missing values (due to gaps in sample collection, discharge, or death) are handled by carrying forward the last observation.\n\nThe Day 28 visit includes a Â±7-day visit window. The priority for defining the ctNP value for this timepoint, according to days post-randomization, is: 28, 27, 29, 26, 30, 25, 31, 24, 32, 23, 33, 22, 34, 21. For example, the ctNP result from the sample collected 26 days post-randomization will only be used for this timepoint if there are no sample results for 28, 27, or 29 days post-randomization.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.1","spread":null},{"groupId":"OG001","value":"23.4","spread":null},{"groupId":"OG002","value":"22.8","spread":null},{"groupId":"OG003","value":"23.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2","spread":null},{"groupId":"OG001","value":"23.7","spread":null},{"groupId":"OG002","value":"23.3","spread":null},{"groupId":"OG003","value":"22.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.0","spread":null},{"groupId":"OG001","value":"25.1","spread":null},{"groupId":"OG002","value":"25.2","spread":null},{"groupId":"OG003","value":"23.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.7","spread":null},{"groupId":"OG001","value":"28.6","spread":null},{"groupId":"OG002","value":"28.1","spread":null},{"groupId":"OG003","value":"24.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.4","spread":null},{"groupId":"OG001","value":"30.9","spread":null},{"groupId":"OG002","value":"30.5","spread":null},{"groupId":"OG003","value":"25.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6","spread":null},{"groupId":"OG001","value":"32.7","spread":null},{"groupId":"OG002","value":"32.7","spread":null},{"groupId":"OG003","value":"29.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.1","spread":null},{"groupId":"OG001","value":"34.4","spread":null},{"groupId":"OG002","value":"34.5","spread":null},{"groupId":"OG003","value":"32.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.6","spread":null},{"groupId":"OG001","value":"36.3","spread":null},{"groupId":"OG002","value":"36.3","spread":null},{"groupId":"OG003","value":"33.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.2","spread":null},{"groupId":"OG001","value":"39.1","spread":null},{"groupId":"OG002","value":"39.8","spread":null},{"groupId":"OG003","value":"35.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.6","spread":null},{"groupId":"OG001","value":"45.0","spread":null},{"groupId":"OG002","value":"45.0","spread":null},{"groupId":"OG003","value":"38.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Serious Adverse Events/AEs","description":"The number of Serious Adverse Events that were tentatively ascribed to one of the four treatment arms by the site investigator and, upon extensive further review and adjudication by an independent Pharmacovigilance committee, were still felt potentially attributable to study drug as opposed to the underlying Ebola infection.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":175},"commonTop":["incomplete study drug infusion(s)"]}}}